Which has preferable earnings and valuation, ORIC or ERAS?

Erasca is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is ORIC or ERAS more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Erasca N/A -38.43% -32.05%

Does the media favor ORIC or ERAS?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 6 mentions for Erasca. Erasca's average media sentiment score of 0.51 beat Oric Pharmaceuticals' score of 0.23 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GRFS or ORIC?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Oric Pharmaceuticals' score of 0.23 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNTH or ORIC?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.46 beat Oric Pharmaceuticals' score of 0.23 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, EWTX or ORIC?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is EWTX or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media refer more to EWTX or ORIC?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.29 beat Oric Pharmaceuticals' score of 0.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ORIC or ABCL?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for AbCellera Biologics. Oric Pharmaceuticals' average media sentiment score of 0.23 beat AbCellera Biologics' score of 0.20 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oric Pharmaceuticals (ORIC) Competitors

$11.99 -0.04 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$12.00 +0.01 (+0.08%)

As of 07:30 PM Eastern

Compare

ORIC vs. ERAS, GRFS, DNTH, EWTX, and ABCL

Should you buy Oric Pharmaceuticals stock or one of its competitors? Oric Pharmaceuticals's main competitors and comparable companies include Erasca (ERAS), Grifols (GRFS), Dianthus Therapeutics (DNTH), Edgewise Therapeutics (EWTX), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oric Pharmaceuticals compare to Erasca?

Oric Pharmaceuticals (NASDAQ:ORIC) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Erasca is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Oric Pharmaceuticals presently has a consensus price target of $20.67, indicating a potential upside of 71.79%. Erasca has a consensus price target of $22.09, indicating a potential upside of 42.89%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Oric Pharmaceuticals' return on equity of -35.35% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Erasca	N/A	-38.43%	-32.05%

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 6 mentions for Erasca. Erasca's average media sentiment score of 0.51 beat Oric Pharmaceuticals' score of 0.23 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Erasca has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Oric Pharmaceuticals beats Erasca on 8 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Oric Pharmaceuticals' score of 0.23 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Grifols has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.59	$454.82M	$0.19	39.00
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 34.95%. Oric Pharmaceuticals has a consensus target price of $20.67, indicating a potential upside of 71.79%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Grifols has a net margin of 5.54% compared to Oric Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Summary

Grifols beats Oric Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Dianthus Therapeutics presently has a consensus target price of $129.83, suggesting a potential upside of 57.51%. Oric Pharmaceuticals has a consensus target price of $20.67, suggesting a potential upside of 71.79%. Given Oric Pharmaceuticals' higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.46 beat Oric Pharmaceuticals' score of 0.23 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Oric Pharmaceuticals has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.90M	2,372.37	-$162.34M	-$4.15	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Summary

Oric Pharmaceuticals beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals' return on equity of -35.35% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.29 beat Oric Pharmaceuticals' score of 0.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics presently has a consensus price target of $51.33, indicating a potential upside of 30.85%. Oric Pharmaceuticals has a consensus price target of $20.67, indicating a potential upside of 71.79%. Given Oric Pharmaceuticals' higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Edgewise Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Summary

Oric Pharmaceuticals beats Edgewise Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to AbCellera Biologics?

Oric Pharmaceuticals (NASDAQ:ORIC) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Oric Pharmaceuticals has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Oric Pharmaceuticals currently has a consensus target price of $20.67, indicating a potential upside of 71.79%. AbCellera Biologics has a consensus target price of $13.38, indicating a potential upside of 11.27%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Oric Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oric Pharmaceuticals has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
AbCellera Biologics	$75.13M	49.05	-$146.41M	-$0.54	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Oric Pharmaceuticals and 2 mentions for AbCellera Biologics. Oric Pharmaceuticals' average media sentiment score of 0.23 beat AbCellera Biologics' score of 0.20 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Summary

Oric Pharmaceuticals beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.24B	$3.90B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-8.88	13.55	274.76	26.18
Price / Sales	N/A	1,283.29	632.15	98.25
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	3.07	17.17	11.21	6.34
Net Income	-$129.47M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-1.72%	-1.20%	-0.84%	-1.39%
1 Month Performance	-4.08%	-9.68%	-5.42%	-4.31%
1 Year Performance	-14.84%	10.09%	4.38%	-0.35%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	3.1445 of 5 stars	$11.99 -0.3%	$20.67 +72.4%	-15.8%	$1.25B	N/A	N/A	111
ERAS Erasca	2.5692 of 5 stars	$14.72 -0.1%	$22.09 +50.1%	+536.2%	$5.16B	N/A	N/A	103
GRFS Grifols	4.3008 of 5 stars	$7.41 +1.4%	$10.00 +35.0%	-23.1%	$4.98B	$8.51B	39.00	25,247	News Coverage Short Interest Increase
DNTH Dianthus Therapeutics	2.5724 of 5 stars	$88.04 -0.2%	$129.83 +47.5%	+137.2%	$4.83B	$1.90M	N/A	92	News Coverage
EWTX Edgewise Therapeutics	2.824 of 5 stars	$40.30 -2.7%	$51.33 +27.4%	+155.6%	$4.50B	N/A	N/A	127

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ERAS, GRFS, DNTH, EWTX, and ABCL

How does Oric Pharmaceuticals compare to Erasca?

Summary

How does Oric Pharmaceuticals compare to Grifols?

Summary

How does Oric Pharmaceuticals compare to Dianthus Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Oric Pharmaceuticals compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ERAS, GRFS, DNTH, EWTX, and ABCL

How does Oric Pharmaceuticals compare to Erasca?

Do insiders & institutionals have more ownership in ORIC or ERAS?

Which has preferable earnings and valuation, ORIC or ERAS?

Do analysts rate ORIC or ERAS?

Is ORIC or ERAS more profitable?

Does the media favor ORIC or ERAS?

Which has more risk & volatility, ORIC or ERAS?

Summary

How does Oric Pharmaceuticals compare to Grifols?

Does the media refer more to GRFS or ORIC?

Which has more volatility and risk, GRFS or ORIC?

Which has higher earnings & valuation, GRFS or ORIC?

Do insiders and institutionals believe in GRFS or ORIC?

Do analysts prefer GRFS or ORIC?

Is GRFS or ORIC more profitable?

Summary

How does Oric Pharmaceuticals compare to Dianthus Therapeutics?

Do analysts prefer DNTH or ORIC?

Do insiders & institutionals have more ownership in DNTH or ORIC?

Is DNTH or ORIC more profitable?

Does the media prefer DNTH or ORIC?

Which has more risk and volatility, DNTH or ORIC?

Which has preferable earnings & valuation, DNTH or ORIC?

Summary

How does Oric Pharmaceuticals compare to Edgewise Therapeutics?

Do insiders and institutionals have more ownership in EWTX or ORIC?

Which has stronger valuation and earnings, EWTX or ORIC?

Is EWTX or ORIC more profitable?

Does the media refer more to EWTX or ORIC?

Do analysts recommend EWTX or ORIC?

Which has more volatility & risk, EWTX or ORIC?

Summary

How does Oric Pharmaceuticals compare to AbCellera Biologics?

Which has more volatility & risk, ORIC or ABCL?

Do analysts rate ORIC or ABCL?

Which has higher valuation & earnings, ORIC or ABCL?

Do insiders & institutionals believe in ORIC or ABCL?

Does the media prefer ORIC or ABCL?

Is ORIC or ABCL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools